There are many immune mediated diseases with a well-known pathophysiology that have neither a safe and effective treatment, or whose available drugs are efficient but present an elevated toxicity. Immunopathologies affect approximately 3 - 5% of the general population.
Currently therapies used directly for immune mediated diseases, although effective, have a high toxicity and must be used long term. These include corticosteroids, non-steroidal anti-inflammatory drugs and monoclonal antibodies. All adverse reactions produced by these molecules are an important factor influencing patient adhesion to treatment. Advancements in non-steroidal molecules, acting in a specific target way and consisting in a very promissory class, are in development too. Diverse molecules have been studied in relation to immune disease modulation and progress, including those aiming to discover new chemical entities (acetylated salicylates, non-acetylated salicylates, propionic acids, acetic acids, enolic acids, anthranilic acids, naphthylalanine and selective COX-2 inhibitors).
These new molecules or activities expand the possibility of discovering new medicines to treat immune mediated conditions which are less toxic and more effective. This could provide a step for improving the quality of life and increasing the life expectancy of diagnosed patients.
The scope of this Research Topic is to provide a platform for research into the development of novel
drugs to treat inflammatory diseases and immune mediate diseases. We welcome Original Research, Systematic Reviews, Mini Reviews, Data Reports, Case reports and Opinions that focus on, but are not limited to, the following:
• Heterogeneity within inflammatory diseases
• Challenges and trends in the discovery and developing anti-inflammatory drugs
• The poor clinical predictivity of experimental models of inflammatory diseases
• Improving on treating inflammation
• Relationships between pharmaceutical and biotechnology industries in the drug development process
There are many immune mediated diseases with a well-known pathophysiology that have neither a safe and effective treatment, or whose available drugs are efficient but present an elevated toxicity. Immunopathologies affect approximately 3 - 5% of the general population.
Currently therapies used directly for immune mediated diseases, although effective, have a high toxicity and must be used long term. These include corticosteroids, non-steroidal anti-inflammatory drugs and monoclonal antibodies. All adverse reactions produced by these molecules are an important factor influencing patient adhesion to treatment. Advancements in non-steroidal molecules, acting in a specific target way and consisting in a very promissory class, are in development too. Diverse molecules have been studied in relation to immune disease modulation and progress, including those aiming to discover new chemical entities (acetylated salicylates, non-acetylated salicylates, propionic acids, acetic acids, enolic acids, anthranilic acids, naphthylalanine and selective COX-2 inhibitors).
These new molecules or activities expand the possibility of discovering new medicines to treat immune mediated conditions which are less toxic and more effective. This could provide a step for improving the quality of life and increasing the life expectancy of diagnosed patients.
The scope of this Research Topic is to provide a platform for research into the development of novel
drugs to treat inflammatory diseases and immune mediate diseases. We welcome Original Research, Systematic Reviews, Mini Reviews, Data Reports, Case reports and Opinions that focus on, but are not limited to, the following:
• Heterogeneity within inflammatory diseases
• Challenges and trends in the discovery and developing anti-inflammatory drugs
• The poor clinical predictivity of experimental models of inflammatory diseases
• Improving on treating inflammation
• Relationships between pharmaceutical and biotechnology industries in the drug development process
